Development of egfr-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer

Pharmaceutical Research

Volumn 31, Issue 9, 2014, Pages 2490-2502

  Ganta, Srinivas ^a   Singh, Amit ^b   Patel, Niravkumar R ^a   Cacaccio, Joseph ^c   Rawal, Yashesh H ^c   Davis, Barbara J ^a   Amiji, Mansoor M ^b   Coleman, Timothy P ^a,b,c,d  

^a Nemucore Medical Innovations Inc   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c Blue Ocean Biomanufacturing Inc   (United States)

^d Foundation for the Advancement of Personalized Medicine Manufacturing   (United States)

Author keywords

C6 ceramide; EGFR; gadolinium; MRI; nanoemulsion; ovarian cancer; platinum

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE; DRUG CARRIER; EMULSION; ENHANCED GREEN FLUORESCENT PROTEIN; GADOLINIUM; GREEN FLUORESCENT PROTEIN; N-CAPROYLSPHINGOSINE; PEPTIDE; PLATINUM COMPLEX;

AMINO ACID SEQUENCE; CELL SURVIVAL; CHEMISTRY; DIAGNOSTIC USE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EMULSION; FEMALE; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; GADOLINIUM; GREEN FLUORESCENT PROTEINS; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR SEQUENCE DATA; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OVARY; PEPTIDES;

EID: 84896421960     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1345-z     Document Type: Article

References (40)

1. Neijt JP, Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer. 1991;27(11):1367-72.
2. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99(9):2467-98.
3. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev. 1999;99(9):2451-66.
4. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-20.
5. Stathopoulos GP. Liposomal cisplatin: a new cisplatin formulation. Anticancer Drugs. 2010;21(8):732-6.
6. Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, et al. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002;13(1):167-76.
7. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-61.
8. Talekar M, Ganta S, Singh A, Amiji M, Kendall J, Denny WA, et al. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells. Pharm Res. 2012;29(10):2874-86.
9. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6(3):928-39.
10. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci. 2010;99(11):4630-41.
11. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv. 2005;2(4):297-310.
12. Ganta S, Devalapally H, Baguley BC, Garg S, Amiji M. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J Biomed Nanotechnol. 2008;4(2):165-73.
13. Ganta S, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm. 2008;360(1-2):115-21.
14. Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010;27(7):260-73.
15. Ganta S, Sharma P, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. J Drug Target. 2010;18(2):125-33.
16. Maeda M, Sasaki T, inventors; Sumitomo Pharmaceuticals Company Ltd, assignee. Liposoluble platinum (II) complex and preparation thereof. US 6,613,799 B1; 2003.
17. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 2002;240(1-2):95-102.
18. Tiwari S, Tan YM, Amiji M. Preparation and in vitro characterization of multifunctional nanoemulsions for simultaneous MR imaging and targeted drug delivery. J Biomed Nanotechnol. 2006;2(3-4):3-4.
19. Nagaraja TN, Croxen RL, Panda S, Knight RA, Keenan KA, Brown SL, et al. Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent. J Neurosci Methods. 2006;157(2):238-45.
20. Clogston JD, Patri AK. Detecting and measuring free gadolinium in nanoparticles for MRI imaging. In: McNeil SE, editor. Methods in Molecular Biology: Characterization of nanoparticles intended for drug delivery. New York: Human Press; 2011. p. 101-8.
21. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994;86(20):1517-24.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27-55.
23. Milane L, Duan ZF, Amiji M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine. 2011;7(4):435-44.
24. Milane L, Duan Z, Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One. 2011;6(9):e24075.
25. Milane L, Duan Z, Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm. 2011;8(1):185-203.
26. Xu J, Amiji M. Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles. J Vis Exp. 2012;59:e3612.
27. Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363(1-2):155-61.
28. Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19(14):1978-85.
29. Grant CW, Karlik S, Florio E. A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn Reson Med. 1989;11(2):236-43.
30. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60(3):314-23.
31. Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A. 2010;107(28):12435-40.
32. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706-21.
33. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99(2):415-21.
34. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007;67(10):4843-50.
35. Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer. 2007;121(8):1830-8.
36. Zhang X, Wu X, Li J, Sun Y, Gao P, Zhang C, et al. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. J Surg Oncol. 2011;104(5):466-71.
37. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 2007;11(6):498-512.
38. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, et al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011;2:e117.
39. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res. 2005;11(9):3465-74.
40. Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta. 2003;1612(1):98-106.